BluePrint Better Predictor of Adjuvant Chemo Response than IHC/FISH in Agendia Study | GenomeWeb

NEW YORK (GenomeWeb) — Data from the Neoadjuvant Breast Registry Symphony Trial, led by Pat Whitworth of the Nashville Breast Center and funded by Agendia, have confirmed earlier findings supporting Agendia's BluePrint molecular subtyping assay as a more effective predictor of adjuvant chemotherapy response than classification by immunohistochemistry and FISH testing.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PLOS this week: RNA-seq, ChIP-seq to determine metformin response; array-based approach to detect protozoa in blood; and more.

Fast Company takes a look at startups in the nutrigenomic space that aim to offer personalized diet advice.

In a glamorous event, the Breakthrough Foundation gave out more than $25 million in prizes to researchers.

Immunotherapy might treat cancer, but it also appears to come with a risk of a number of side effects, the New York Times reports.